Trial Profile
A Pivotal Phase 3 Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 03 Apr 2024
Price :
$35
*
At a glance
- Drugs Dabocemagene autoficel (Primary)
- Indications Epidermolysis bullosa dystrophica
- Focus Registrational; Therapeutic Use
- Acronyms DEFI-RDEB
- Sponsors Fibrocell Science; Fibrocell Technologies
- 10 Aug 2022 Planned primary completion date changed from 1 Apr 2023 to 1 Feb 2023.
- 10 Aug 2022 Status changed from recruiting to active, no longer recruiting.
- 25 May 2022 According to a Castle Creek Biosciences media release, the financing is expected to provide sufficient capital for the company's completion of a Phase 3 study